The United States has approved a potential $2 billion arms sale package to Taiwan, the Pentagon said on Friday, including the delivery for the first time to the island of an advanced air defense ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

The FDA has cleared Iterum’s oral an­tibi­ot­ic for cer­tain pa­tients with un­com­pli­cat­ed uri­nary tract in­fec­tions (uUTIs) who have lim­it­ed or no al­ter­na­tive oral op ...

2024 Healthcare & Pharmaceuticalscategory US FDA approves Johnson & Johnson's device for heart condition November 7, 2024 Healthcare & Pharmaceuticalscategory Americans hungry for weight-loss ...

Sulopenem, which will now go by the commercial moniker Orlynvah, was approved by the FDA Friday to treat uncomplicated urinary tract infections (uUTIs) caused by E. coli, Klebsiella pneumoniae or ...

The US government has approved the construction of a massive new lithium mine on public land in Nevada as part of a strategy to break China’s dominance over the supply chain of critical minerals ...

(RTTNews) - Iterum Therapeutics plc (ITRM) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Iterum's new drug application for Orlynvah (sulopenem etzadroxil and ...

ORLYNVAH™ is the first oral penem approved for use in the ... To report SUSPECTED ADVERSE REACTIONS, contact Iterum Therapeutics plc at 1-866-414-SULO or FDA at 1-800-FDA-1088 or www.fda.gov ...

25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections ...

Approval is based on phase 3 SURE 1 and REASSURE trials, highlighting its potential as a community treatment alternative. The FDA's advisory committee emphasized the need for a narrow indication and ...